(MO) Altria - Overview
Sector: Consumer Defensive | Industry: Tobacco | Exchange: NYSE (USA) | Market Cap: 120.549m USD | Total Return: 30.8% in 12m
Avg Turnover: 563M
EPS Trend: 93.9%
Qual. Beats: 1
Rev. Trend: 33.3%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Idiosyncratic Leader, Confidence
Altria Group, Inc. is a Richmond-based manufacturer and distributor of smokeable and oral tobacco products operating exclusively within the United States market. Its core portfolio includes the Marlboro cigarette brand, Black & Mild cigars, and various smokeless tobacco labels such as Copenhagen and Skoal. The company has expanded into reduced-risk categories through its on! oral nicotine pouches and NJOY ACE e-vapor products.
The company operates within a highly regulated GICS Tobacco sub-industry characterized by significant barriers to entry and high pricing power, which historically offsets declining cigarette shipment volumes. Altria utilizes a direct-to-retail and distributor-based wholesale model to maintain its dominant domestic market share. Investors may find it useful to examine historical dividend sustainability and regulatory filings on ValueRay to further understand company risks. Altria’s transition toward smoke-free products remains a central component of its long-term business strategy as consumer preferences shift away from traditional combustible products.
- Marlboro cigarette volume declines necessitate continued aggressive retail price increases
- FDA regulatory scrutiny of flavored tobacco and nicotine pouches threatens growth
- NJOY e-vapor expansion determines success of cigarette-to-smoke-free transition
- High dividend yield and share buybacks depend on consistent free cash flow
- Oral nicotine pouch market share gains offset traditional smokeless tobacco weakness
| Net Income: 8.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA 1.30 > 1.0 |
| NWC/Revenue: -17.10% < 20% (prev -22.60%; Δ 5.50% < -1%) |
| CFO/TA 0.26 > 3% & CFO 8.89b > Net Income 8.05b |
| Net Debt (21.1b) to EBITDA (11.7b): 1.80 < 3 |
| Current Ratio: 0.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.67b) vs 12m ago -1.01% < -2% |
| Gross Margin: 67.84% > 18% (prev 70.81%; Δ -2.97% > 0.5%) |
| Asset Turnover: 62.02% > 50% (prev 56.62%; Δ 5.41% > 0%) |
| Interest Coverage Ratio: 10.68 > 6 (EBIT TTM 11.5b / Interest Expense TTM 1.07b) |
| A: -0.11 (Total Current Assets 4.68b - Total Current Liabilities 8.41b) / Total Assets 34.6b |
| B: 1.04 (Retained Earnings 35.9b / Total Assets 34.6b) |
| C: 0.33 (EBIT TTM 11.5b / Avg Total Assets 35.2b) |
| D: -0.09 (Book Value of Equity -3.21b / Total Liabilities 37.7b) |
| Altman-Z'' = 4.78 = AA |
| DSRI: 1.02 (Receivables 284.0m/258.0m, Revenue 21.8b/20.2b) |
| GMI: 1.04 (GM 70.81% / 67.84%) |
| AQI: 1.04 (AQ_t 0.81 / AQ_t-1 0.79) |
| SGI: 1.08 (Revenue 21.8b / 20.2b) |
| TATA: -0.02 (NI 8.05b - CFO 8.89b) / TA 34.6b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of June 09, 2026, the stock is trading at USD 72.19 with a total of 8,057,598 shares traded.
Over the past week, the price has changed by +3.75%,
over one month by +4.56%,
over three months by +9.49% and
over the past year by +30.81%.
Altria has received a consensus analysts rating of 3.27. Therefore, it is recommended to hold MO.
- StrongBuy: 3
- Buy: 1
- Hold: 9
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 70.4 | -2.5% |
P/E Trailing = 15.071
P/E Forward = 12.8866
P/S = 5.9157
P/B = 25.2407
P/EG = 1.6527
Revenue TTM = 21.8b USD
EBIT TTM = 11.5b USD
EBITDA TTM = 11.7b USD
Long Term Debt = 24.1b USD (from longTermDebt, last quarter)
Short Term Debt = 542.0m USD (from shortTermDebt, last quarter)
Debt = 24.6b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.1b USD (calculated: Debt 24.6b - CCE 3.53b)
Enterprise Value = 142b USD (121b + Debt 24.6b - CCE 3.53b)
Interest Coverage Ratio = 10.68 (Ebit TTM 11.5b / Interest Expense TTM 1.07b)
EV/FCF = 16.42x (Enterprise Value 142b / FCF TTM 8.62b)
FCF Yield = 6.09% (FCF TTM 8.62b / Enterprise Value 142b)
FCF Margin = 39.53% (FCF TTM 8.62b / Revenue TTM 21.8b)
Net Margin = 36.91% (Net Income TTM 8.05b / Revenue TTM 21.8b)
Gross Margin = 67.84% ((Revenue TTM 21.8b - Cost of Revenue TTM 7.02b) / Revenue TTM)
Gross Margin QoQ = 64.59% (prev 62.11%)
Tobins Q-Ratio = 4.09 (Enterprise Value 142b / Total Assets 34.6b)
Interest Expense / Debt = 4.37% (Interest Expense 1.07b / Debt 24.6b)
Taxrate = 23.78% (2.51b / 10.6b)
NOPAT = 8.75b (EBIT 11.5b * (1 - 23.78%))
Current Ratio = 0.56 (Total Current Assets 4.68b / Total Current Liabilities 8.41b)
Debt / Equity = -7.66 (negative equity) (Debt 24.6b / totalStockholderEquity, last quarter -3.21b)
Debt / EBITDA = 1.80 (Net Debt 21.1b / EBITDA 11.7b)
Debt / FCF = 2.44 (Net Debt 21.1b / FCF TTM 8.62b)
Total Stockholder Equity = -3.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 22.90% (Net Income 8.05b / Total Assets 34.6b)
RoE = -255.3% (negative equity) (Net Income TTM 8.05b / Total Stockholder Equity -3.15b)
RoCE = 54.91% (EBIT 11.5b / Capital Employed (Equity -3.15b + L.T.Debt 24.1b))
RoIC = 34.14% (NOPAT 8.75b / Invested Capital 25.6b)
WACC = 5.06% (E(121b)/V(145b) * Re(5.41%) + D(24.6b)/V(145b) * Rd(4.37%) * (1-Tc(0.24)))
Discount Rate = 5.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.88 | Cagr: -2.43%
[DCF] Terminal Value 75.71% ; FCFF base≈8.55b ; Y1≈8.73b ; Y5≈9.57b
[DCF] Fair Price = 76.19 (EV 148b - Net Debt 21.1b = Equity 127b / Shares 1.67b; r=8.35% [WACC [floored]]; 5y FCF grow 2.04% → 2.50% )
EPS Correlation: 93.93 | EPS CAGR: 4.61% | SUE: 2.30 | # QB: 1
Revenue Correlation: 33.25 | Revenue CAGR: 0.79% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.49 | Chg30d=+1.45% | Revisions=+67% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.50 | Chg30d=-0.42% | Revisions=-17% | Analysts=11
EPS current Year (2026-12-31): EPS=5.68 | Chg30d=+1.01% | Revisions=+73% | GrowthEPS=+4.8% | GrowthRev=+1.9%
EPS next Year (2027-12-31): EPS=5.87 | Chg30d=+1.02% | Revisions=+73% | GrowthEPS=+3.4% | GrowthRev=+0.7%
[Analyst] Revisions Ratio: +73%